Short Interest in Equillium, Inc. (NASDAQ:EQ) Rises By 620.6%

Equillium, Inc. (NASDAQ:EQ) was the target of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 672,300 shares, an increase of 620.6% from the January 31st total of 93,300 shares. Based on an average daily trading volume, of 771,000 shares, the short-interest ratio is currently 0.9 days. Approximately 3.9% of the shares of the company are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Equillium stock. Takeda Pharmaceutical Co. Ltd. acquired a new stake in Equillium, Inc. (NASDAQ:EQ) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,824,977 shares of the company’s stock, valued at approximately $1,369,000. Equillium accounts for 5.2% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its 4th largest holding. Takeda Pharmaceutical Co. Ltd. owned approximately 5.15% of Equillium as of its most recent SEC filing. 27.05% of the stock is owned by institutional investors.

Equillium Stock Performance

Shares of EQ stock traded up $0.00 during mid-day trading on Friday, reaching $0.76. The company’s stock had a trading volume of 45,348 shares, compared to its average volume of 1,202,996. The firm’s 50-day moving average is $0.75 and its two-hundred day moving average is $0.82. Equillium has a 1-year low of $0.49 and a 1-year high of $2.99. The company has a market cap of $27.07 million, a P/E ratio of -5.46 and a beta of 1.79.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.